Arthritis, Psoriatic Clinical Trial
Official title:
Long-term Documentation on the Use of Apremilast in Patients With Psoriatic Arthritis in Practice Conditions
A total of approximately 500 patients with active psoriatic arthritis in an estimated 80 to 100 trial centers are to be enrolled. Selection of centers will be made by the sponsor's medical section. To increase the quality of the data and to reduce distribution of the data collected, centers to be included will be those which can enroll at least 5 patients. Care will be taken to ensure a balanced regional distribution. The proposed observation period for the trial is approx. 52 weeks per patient. Estimated patient enrolment is also 52 weeks. The duration of the follow-up period will be extended from approx. 52 weeks to approx. 100 weeks to gain further information about the long-term use of Otezla®. For this extension of the follow-up period 2 new visits (visits 6 and 7) are proposed.Thus, proposed duration from first patient in (FPI) to last patient out (LPO) is 36 months-
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02181673 -
A Study of Golimumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
Recruiting |
NCT04936308 -
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
|
Phase 3 | |
Terminated |
NCT00090129 -
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Withdrawn |
NCT03625089 -
Impact of Nurse-led Programme With Carotid Ultrasound on Addressing Cardiovascular Risk in Patients With Arthritis
|
N/A | |
Recruiting |
NCT05571696 -
Mind Matters: A High Touch, Low Cost Approach to Improving Mental Health Outcomes in Patients With Psoriatic Diseases
|
N/A | |
Active, not recruiting |
NCT05071664 -
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis
|
Phase 2 | |
Completed |
NCT00938015 -
Study Evaluating Safety and Adherence to Treatment With Etanercept in Adults With Psoriatic Arthritis
|
N/A | |
Suspended |
NCT03703934 -
Central Pain Mechanisms in Patients With Hand-Osteoarthritis, Psoriatic Arthritis and Healthy Controls
|
||
Recruiting |
NCT05092269 -
A Long-term Extension Study of Ustekinumab in Pediatric Participants
|
Phase 3 | |
Terminated |
NCT05083078 -
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
|
Phase 1 | |
Completed |
NCT02436785 -
Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?
|
N/A | |
Completed |
NCT02294227 -
16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis
|
Phase 3 | |
Completed |
NCT00998829 -
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
|
N/A | |
Completed |
NCT00760669 -
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
|
Phase 4 | |
Completed |
NCT00367237 -
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
|
Phase 3 | |
Completed |
NCT00051623 -
A Study of the Safety and Effectiveness of Infliximab for the Treatment of Psoriatic Arthritis
|
Phase 3 | |
Withdrawn |
NCT04680676 -
A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis
|
Phase 2 | |
Completed |
NCT03008590 -
Low Dose Naltrexone for Chronic Pain From Arthritis
|
Phase 2 | |
Recruiting |
NCT05657847 -
Novel Complex Radiodiagnostics of Peripherial Arthropathies
|
||
Completed |
NCT02875184 -
A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands
|